Korean J Gastroenterol.  2011 Jun;57(6):384-387. 10.4166/kjg.2011.57.6.384.

Hepatocellular Adenoma Treated with Radiofrequency Ablation in Young Male

• Kim T
• Kim BS
• Hyun CL
• Song BC

• KMID: 1792805
• DOI: http://doi.org/10.4166/kjg.2011.57.6.384

Abstract

No abstract available.

Figure

• 

  Fig. 1. Radiologic features of hepatocelluar adenoma. (A) Ultrasonographic image showed an approximately 2.4 cm sized hypoechoic nodule in the segment 2. (B) Computed tomography (CT) image on hepatic arterial phase showed well-demarcated and homogeneous enhancing nodule in the segment 2. (C) CT image on delayed phase showed that the nodule became isodense or slightly hyperdense, compared with the liver parenchyma. (D) Three-month follow-up ultrasonographic image showed increased size (3.3 cm). (E) T1-weighted magnetic resonance (MR) image showed a well-defined high signal intensity nodule in the segment 2. (F) T2-weighted MR image showed slightly high signal intensity in nodule, compared with the liver parenchyma. (G) Gd-EOB-DTPA contrast-enhanced T1-weighted MR image on hepatic arterial phase showed homogenous enhancement of the nodule. (H) Gd-EOB-DTPA contrast-enhanced T1-weighted MR image on delayed hepatocyte dominant phase showed no contrast uptake in the hepatic nodule. (I) Ten-month follow-up CT image showed no recurrence after radiofrequency ablation. Gd-EOB-DTPA, Gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid.

• 

  Fig. 2. Pathological features of hepatocelluar adenoma. (A) The tumor cells were composed of fairly uniform hepatocytes arranged without atypism (Haematoxylin Eosin, ×200). (B) Immunohistochemical stain for CD34 revealed randomly arranged parenchymal vessel (black arrow) (×200). (C) Immunohistochemical stain for CK19 revealed no bile duct or biliary epithelial cells.

Reference

References

1. Rooks JB, Ory HW, Ishak KG, Strauss LT, Greenspan JR, Tyler CW Jr. The association between oral contraception and hepatocellular adenoma–a preliminary report. Int J Gynaecol Obstet. 1977; 15:143–144.

2. Dokmak S, Paradis V, Vilgrain V, et al. A single-center surgical experience of 122 patients with single and multiple hepatocellular adenomas. Gastroenterology. 2009; 137:1698–1705.

3. Klatskin G. Hepatic tumors: possible relationship to use of oral contraceptives. Gastroenterology. 1977; 73:386–394.

4. Choi NS, Kim BH, Lee SB, et al. Clinical review of hepatic adenoma reported in Korea. Korean J Med. 1998; 54:627–632.

5. Lin H, van den Esschert J, Liu C, van Gulik TM. Systematic review of hepatocellular adenoma in China and other regions. J Gastroenterol Hepatol. 2011; 26:28–35.

6. Gyorffy EJ, Bredfeldt JE, Black WC. Transformation of hepatic cell adenoma to hepatocellular carcinoma due to oral contraceptive use. Ann Intern Med. 1989; 110:489–490.

7. Rooks JB, Ory HW, Ishak KG, et al. Epidemiology of hepatocellular adenoma. The role of oral contraceptive use. JAMA. 1979; 242:644–648.

8. Labrune P, Trioche P, Duvaltier I, Chevalier P, Odièvre M. Hepatocellular adenomas in glycogen storage disease type I and III: a series of 43 patients and review of the literature. J Pediatr Gastroenterol Nutr. 1997; 24:276–279.

9. Martin NM, Abu Dayyeh BK, Chung RT. Anabolic steroid abuse causing recurrent hepatic adenomas and hemorrhage. World J Gastroenterol. 2008; 14:4573–4575.

10. Socas L, Zumbado M, Pérez-Luzardo O, et al. Hepatocellular adenomas associated with anabolic androgenic steroid abuse in bodybuilders: a report of two cases and a review of the literature. Br J Sports Med. 2005; 39:e27.

11. Leese T, Farges O, Bismuth H. Liver cell adenomas. A 12-year surgical experience from a specialist hepatobiliary unit. Ann Surg. 1988; 208:558–564.

12. Cho SW, Marsh JW, Steel J, et al. Surgical management of hepatocellular adenoma: take it or leave it? Ann Surg Oncol. 2008; 15:2795–2803.

13. Deneve JL, Pawlik TM, Cunningham S, et al. Liver cell adenoma: a multicenter analysis of risk factors for rupture and malignancy. Ann Surg Oncol. 2009; 16:640–648.

14. Harvey CJ, Albrecht T. Ultrasound of focal liver lesions. Eur Radiol. 2001; 11:1578–1593.

15. Golli M, Van Nhieu JT, Mathieu D, et al. Hepatocellular adenoma: color Doppler US and pathologic correlations. Radiology. 1994; 190:741–744.

16. Grazioli L, Federle MP, Brancatelli G, Ichikawa T, Olivetti L, Blachar A. Hepatic adenomas: imaging and pathologic findings. Radiographics. 2001; 21:877–892.

17. Arrivé L, Fléjou JF, Vilgrain V, et al. Hepatic adenoma: MR findings in 51 pathologically proved lesions. Radiology. 1994; 193:507–512.

18. Chung KY, Mayo-Smith WW, Saini S, Rahmouni A, Golli M, Mathieu D. Hepatocellular adenoma: MR imaging features with pathologic correlation. AJR Am J Roentgenol. 1995; 165:303–308.

19. Grazioli L, Morana G, Kirchin MA, Schneider G. Accurate differentiation of focal nodular hyperplasia from hepatic adenoma at gadobenate dimeglumine-enhanced MR imaging: prospective study. Radiology. 2005; 236:166–177.

20. Bruix J, Sherman M. American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update. Hepatology. 2011; 53:1020–1022.

21. Atwell TD, Brandhagen DJ, Charboneau JW, Nagorney DM, Callstrom MR, Farrell MA. Successful treatment of hepatocellular adenoma with percutaneous radiofrequency ablation. AJR Am J Roentgenol. 2005; 184:828–831.